TY - JOUR
T1 - Appropriate use of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for atherosclerotic cardiovascular disease
T2 - Comparison of recommendations from different guidelines or consensus around the world
AU - Lin, Jia Ling
AU - Huang, Po Hsun
AU - Yeh, Hung I.
AU - Li, Yi Heng
N1 - Publisher Copyright:
© 2020, Republic of China Society of Cardiology. All rights reserved.
PY - 2020
Y1 - 2020
N2 - Increased low-density lipoprotein cholesterol (LDL-C) is the most crucial risk factor for atherosclerotic cardiovascular disease (ASCVD). Statins are the mainstay therapy, but many patients need to add non-statin treatment to reach the recommended LDL-C goal. Although proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are the most effective agents in LDL-C reduction, they are much more expensive than other lipid-lowering agents. In January 2020, the Taiwan National Health Insurance (NHI) program started to reimburse PCSK9 inhibitors for select ASCVD patients with certain conditions. Major guidelines or consensus worldwide also provide specific recommendations about how to appropriately use these agents. This review summarizes the Taiwan NHI regulations of using PCSK9 inhibitors and compared them with other guidelines or consensus around the world.
AB - Increased low-density lipoprotein cholesterol (LDL-C) is the most crucial risk factor for atherosclerotic cardiovascular disease (ASCVD). Statins are the mainstay therapy, but many patients need to add non-statin treatment to reach the recommended LDL-C goal. Although proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are the most effective agents in LDL-C reduction, they are much more expensive than other lipid-lowering agents. In January 2020, the Taiwan National Health Insurance (NHI) program started to reimburse PCSK9 inhibitors for select ASCVD patients with certain conditions. Major guidelines or consensus worldwide also provide specific recommendations about how to appropriately use these agents. This review summarizes the Taiwan NHI regulations of using PCSK9 inhibitors and compared them with other guidelines or consensus around the world.
UR - http://www.scopus.com/inward/record.url?scp=85091061428&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85091061428&partnerID=8YFLogxK
U2 - 10.6515/ACS.202009_36(5).20200330B
DO - 10.6515/ACS.202009_36(5).20200330B
M3 - Review article
AN - SCOPUS:85091061428
VL - 36
SP - 403
EP - 408
JO - Acta Cardiologica Sinica
JF - Acta Cardiologica Sinica
SN - 1011-6842
IS - 5
ER -